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ABSTRACT
Allogeneic hematopoietic stem cell transplantation (SCT) may cure patients with hematologic malignancies,
but it carries significant risks. Careful donor selection is an important component of the clinical transplantation
decision-making process and includes evaluation of HLA typing and other criteria, the most controversial of
which is parity. We examined the effect of donor sex and parity on outcomes of HLA-identical sibling SCT.
Because the effect of recipient sex/parity has never been explicitly evaluated, we also analyzed the effect of
recipient sex/parity on outcomes of transplantation. We found that (1) parous female donors result in an
increased risk of chronic graft-versus-host disease (GVHD) in all recipients, (2) the magnitude of this increased
risk is similar in male and female recipients, and (3) nulliparous female donors increase the risk of chronic
GVHD in male recipients to a degree comparable to that from parous donors. A decrease in the risk of relapse
was not observed, and there was no effect on overall survival, acute GVHD, or transplant-related mortality.
Recipient parity had no independent effect on any endpoint. Until the effects of pregnancy on the maternal
immune system are better understood, it is appropriate whenever possible to avoid parous female donors and
to choose male donors for male recipients in HLA-identical related donor SCT.
© 2006 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Allogeneic hematopoietic stem cell transplanta-
ion (SCT) is a curative therapy for patients with
ematologic malignancies but results in signiﬁcant
orbidity and mortality. Donor selection is an impor-
ant way that the risks may be decreased and is there-
ore a key component of the clinical practice of trans-
lantation. In general, HLA-identical siblings are the
referred donors, but some patients have more than t
58ne HLA-matched sibling. Thus, it is important to
nderstand the contribution of donor factors other
han HLA matching to outcomes after SCT. Criteria
roved or hypothesized to affect outcomes after SCT
nclude age, cytomegalovirus (CMV) serostatus, ABO
ompatibility, and sex and parity. Of these, sex/parity
s the most controversial, and it is not clear which of
hese factors should outweigh the others. Some inves-
igators have found an increased risk of acute or
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Parity and GVHD 759hronic graft-versus-host disease (GVHD) associated
ith donor parity [1-7], although it is uncertain
hether this risk applies just to male recipients or to
able 1. Summary of Previous Studies of Sex and/or Parity in Allogen
Study Year n
Sex/Parity Combinat
Considered in Stud
ale et al [1] 1987 2036 Sex mismatching
Alloimmunized* female d
male vs female recipien
lowers et al [2] 1990 136 Donor sex/parity ¡ any r
Parous female donor ¡ m
female recipients
tkinson et al [3] 1986 2534 Sex mismatching
Alloimmunized donor
eisdorf et al [4] 1991 469 Sex mismatching
Alloimmunized donor
ash et al [5] 1992 446 Sex mismatching
Donor parity/recipient se
arlens et al [6] 1998 451 Female donor ¡ male re
vs all others
Alloimmunized female do
all other combinations
emberger et al [7] 2002 679 Alloimmunized female do
male recipient vs all ot
combinations
rzepiorka et al [8] 1999 160 Donor sex
Female donor ¡ male re
vs all other combinatio
Alloimmunized donor
Alloimmunized donor ¡
recipient vs all other
combinationss
ross et al [9] 1984 136 Sex mismatching 
andolph et al [10] 2004 3238 Sex mismatching 
Alloimmunized refers to previous pregnancy or transfusion.
aGVHD indicates acute graft-versus-host disease; cGVHD, chronll patients. Conversely, in other studies, parity was bot a risk factor for GVHD [8]. Further, some studies
ave focused on sex mismatching only, without incor-
orating parity [9,10]. These results, summarized in Ta-
GVHD Endpoint Results†
Acute Increased risk of aGVHD in female ¡
male transplants vs all other
combinations
Increased risk of aGVHD in
alloimmunized female ¡ male vs
female recipients
Increased risk of aGVHD in non-
alloimmunized female ¡ male vs
female recipients
No increased risk of aGVHD in
alloimmunized vs non-
alloimmunized female ¡ female
recipients
t Acute Increased risk of aGVHD in recipients
of parous vs nulliparous female
donor grafts
No increased risk of aGVHD in
recipients of parous female vs male
donor grafts
No increased risk of aGVHD in
recipients of parous female donor
¡ male vs female recipients
Chronic Increased risk of cGVHD in
alloimmunized female donors ¡
male vs female recipients
Acute Increased risk of aGVHD in all
combinations other than female
donor/female recipient
Increased risk of aGVHD in
alloimmunized vs non-
alloimmunized donor into all
recipients
Acute Increased risk of aGVHD in female
recipients of male grafts and in
male recipients of parous female
grafts
Chronic Increased risk of cGVHD in
alloimmunized vs non-
alloimmunized donor into all
recipients
Chronic Increased risk of cGVHD in male
recipients of alloimmunized female
donor transplants
Acute No effect of donor sex or parity on
aGVHD
Acute Sex mismatching (either direction)
increases risk of aGVHD
Acute and chronic Increased risk of aGVHD and cGVHD
in male recipients of female grafts
HD.eic SCT
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malele 1, are generally from single centers, contain small
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A. W. Loren et al.760umbers of patients, or were reported before the era
f combination GVHD prophylaxis with a calcineurin
nhibitor plus methotrexate. Thus, it is difﬁcult to
ynthesize the results into a cohesive model of the
ffect of donor parity on outcomes of related-donor
CT that is applicable to current practice. In a Na-
ional Marrow Donor Program analysis of unrelated
onor data, parity was identiﬁed as an independent
isk factor for chronic GVHD [11].
It is hypothesized that pregnancy-induced alloim-
unization is the mechanism underlying the increased
isk of GVHD imparted by parous donors. It is clear
hat there is maternal exposure to fetal antigens: fetal
ells or DNA have been detected in the maternal
irculation in 50% to 100% of women during preg-
ancy [12-15] and are identiﬁed as soon as 5 weeks’
estation [16]. Further, there are ample data to demon-
trate that alloimmunization occurs, as evidenced by
linical phenomena such as rhesus isoimmunization and
eonatal alloimmune thrombocytopenia, and by the
ostpregnancy development of antibodies and/or cyto-
oxic T-cells that recognize epitopes of the rhesus D
rotein [17], platelet antigens [18], HLA [19-21], and
utosomal [22] and Y-chromosome–encoded (H-Y) [22-
6] minor histocompatibility antigens.
The role of previous pregnancies in recipients of
llogeneic SCT has never been evaluated, although
his also has the potential to inﬂuence outcomes and
ay interact with donor parity. Residual recipient
mmunity may remain despite myeloablative condi-
ioning therapy [27], and this persistent immunity is
he presumed cause of graft rejection [28,29].
This study investigated the effect of donor and
ecipient sex/parity on outcomes of HLA-identical
ibling allogeneic SCT in a large cohort of patients.
his is also the ﬁrst study to evaluate the effect of
ecipient sex/parity on outcomes of SCT.
ETHODS
atients
The study population consisted of adults (age 18
ears) who were reported to the Center for International
lood and Marrow Transplant Research (CIBMTR)
nd received a non–T-cell–depleted, myeloablative allo-
eneic SCT from anHLA-identical sibling who was also
18 years old, between 1995 and 1999, for acute lym-
hoblastic or myelogenous leukemia or chronic myelog-
nous leukemia. Characteristics of the population are
isted in Tables 2 and 3.
Donors and recipients were categorized as male,
ulliparous female, or parous (1 pregnancy) female.
ovariables of interest are listed in Table 4. Of note,
bidirectional” ABO incompatibility (eg, type A donor
type B recipient) was classiﬁed as minor, rather
han major, incompatibility. This approach is consis- aent with previous studies of ABO incompatibility in
CT [30-32] and has the effect of maximizing the
ontribution of ABO incompatibility to GVHD. We
elt that this was the most conservative approach.
tudy Endpoints
The primary endpoints of this retrospective co-
ort study included overall survival and acute and
hronic GVHD. Secondary endpoints were relapse
nd transplant-related mortality. Acute GVHD was
resent if graded II-IV according to criteria of
lucksberg et al [33]; cumulative incidence is reported
t 100 days after transplantation. Chronic GVHD
ncluded limited and extensive disease; only patients
urviving past day 100 were considered at risk for this
ndpoint. Cumulative incidence is reported at 2 years
fter transplantation. Transplant-related mortality
as deﬁned as any death within 28 days of transplan-
ation or death in continuous remission.
tatistical Analysis
Analyses were performed with STATA 7.0
STATA Corporation, College Station, Tex) and SAS
.2 (SAS Institute, Cary, NC).
All covariables were compared across the 3 donor
ypes (male, nulliparous female, and parous female;
able 2) and across the 3 groups of recipients (data
ot shown). Categorical variables were compared with
hi-square test. Continuous variables (patient and do-
or age) were compared with the Kruskal-Wallis test.
Univariable analysis. First, the effect of donor sex/
arity was estimated for each primary endpoint (sur-
ival and acute and chronic GVHD), with male do-
ors serving as the reference group. Overall survival
as evaluated with the Kaplan-Meier method, and
roups were compared by using the Tarone-Ware
odiﬁcation of the log-rank test. For acute and
hronic GVHD, cumulative incidence (with death as
competing risk [34,35]) was compared across the 3
onor groups. A separate set of models was then cre-
ted in similar fashion to estimate independently the
ffect of recipient sex/parity on these 3 primary end-
oints. We estimated univariable hazard ratios for
ach covariable (Table 2) for all endpoints. Only those
ovariables that were statistically signiﬁcantly associ-
ted with an endpoint (P  .05) were included in
ultivariable analysis of that endpoint.
Multivariable analysis. For multivariable analyses,
he main effect was the combination of donor and
ecipient sex/parity as presented in Table 3 (9 groups
n total). We used Cox proportional hazards regres-
ion models to estimate the risk of each outcome
or each donor/recipient combination, with the male
onor/male recipient (M-D ¡ M-R) group serving as
he reference. A model was built for each endpoint as
dependent variable and the main effect term for the
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Parity and GVHD 761ex/parity of donor/recipient pairs and all relevant
ovariables (Table 4) as explanatory variables. The
roportional hazards assumption for each variable and
ach endpoint were examined with time-varying co-
ariables. For relapse and transplant-related mortality,
onproportional hazards were identiﬁed for disease
able 2. Patient Characteristics
Male
n  1637 (62)
ecipient
Male 1007 (62)
Nulliparous female 145 (9)
Parous female 485 (30)
ecipient age (y), median (range) 38.3 (18.1-71.5)
onor age (y), median (range) 37.0 (18.0-74.1)
ace
Caucasian 1194 (73)
Other 403 (25)
Missing 40 (2)
isease type*
AML 658 (40)
ALL 273 (17)
CML 706 (43)
isease stage†
Low 1102 (67)
Intermediate 155 (9)
High 350 (21)
Not evaluable 30 (2)
nterval from diagnosis to transplantation
<1 y 1163 (71)
>1 y 474 (29)
VHD prophylaxis‡
CSA  MTX  Other 1338 (82)
Other 299 (18)
otal body irradiation
No 1021 (62)
Yes 616 (38)
tem cell source
Bone marrow 1083 (66)
Peripheral blood stem cells 554 (34)
BO compatibility
Compatible 827 (51)
Minor incompatibility 218 (13)
Major incompatibility 196 (12)
Donor or recipient unknown 396 (24)
istory of donor transfusion
No 1030 (63)
Yes 23 (1)
Unknown 584 (36)
onor/recipient CMV status
Negative/negative 404 (25)
Negative/positive 259 (16)
Positive/negative 158 (10)
Positive/positive 699 (43)
Donor or recipient unknown 117 (7)
AML indicates acute myelogenous leukemia; ALL, acute lymphob
Low-risk disease: ﬁrst remission or ﬁrst chronic phase; intermediat
disease: relapse, primary induction failure, accelerated phase, or
GVHD indicates graft-versus-host disease; CSA, cyclosporine; Mype (acute myelogenous leukemia, acute lymphoblas- eic leukemia, and chronic myelogenous leukemia) and
isease stage (low, intermediate, high, and not evalu-
ble). Thus, Cox regression models were stratiﬁed by
hese variables for those models. A P value .05 was
onsidered statistically signiﬁcant for the main effect
f donor/recipient sex/parity and for the univariable
Donor, n (%)
iparous
male
277 (11)
Parous Female
n  712 (27)
Total
n  2626 P
55) 398 (56) 1558 (59) <.001
19) 62 (9) 260 (10)
26) 252 (35) 808 (31)
18.1-58.8) 39.3 (18.7-62.1) 38.0 (18.1-71.5) .0001
18.0-68.6) 39.0 (19.0-72.1) 37.0 (18.0-74.1) .0001
72) 529 (74) 1923 (73) .93
26) 168 (24) 642 (24)
2) 15 (2) 61 (2)
45) 273 (38) 1055 (40) .03
18) 99 (14) 422 (16)
37) 340 (48) 1149 (44)
67) 467 (66) 1754 (67) .26
14) 76 (11) 269 (10)
17) 156 (22) 553 (21)
3) 13 (2) 50 (2)
75) 498 (70) 1868 (71) .33
25) 214 (30) 758 (29)
81) 572 (80) 2135 (81) .73
19) 140 (20) 491 (19)
60) 450 (63) 1637 (62) .63
40) 262 (37) 989 (38)
72) 472 (66) 1754 (67) .17
28) 240 (34) 872 (33)
52) 354 (50) 1324 (50) .39
16) 83 (12) 346 (13)
9) 91 (13) 313 (12)
23) 184 (26) 643 (24)
76) 441 (62) 1682 (64) <.001
0.3) 36 (5) 60 (2)
23) 235 (33) 884 (34)
30) 160 (22) 647 (25) <.001
16) 71 (10) 373 (14)
12) 66 (9) 258 (10)
37) 373 (52) 1175 (45)
5) 42 (6) 173 (7)
eukemia; CML, chronic myelogenous leukemia.
isease: at least second remission or second chronic phase; high-risk
risis.
ethotrexate.Null
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A. W. Loren et al.762lored interactions between donor sex/parity and re-
ipient sex/parity and between the main effect (donor/
ecipient pairs) and other signiﬁcant explanatory
ariables. There were no statistically signiﬁcant inter-
ctions for any endpoint.
The multivariable analysis described above per-
itted direct comparisons across the 3 donor types
male, nulliparous female, or parous female) for male
ecipients only. Because one of our goals was to enable
transplantation clinician to optimize donor selection
or any patient, male or female, we used pairwise
nalysis to create an additional model that would fa-
ilitate direct comparison of the risks associated with
ach donor type for nulliparous female recipients and
or parous female recipients. Using this analysis, every
ombination of donor/recipient sex/parity was com-
ared with every other possible donor/recipient com-
ination (36 comparisons in all). For clarity, only the
elevant comparisons are reported (ie, risk of chronic
VHD in parous female donor/male recipient pairs vs
ulliparous female donor/nulliparous female recipient
airs is not reported). With 36 subgroups in this pair-
ise analysis, there is a clear need to adjust for multiple
omparisons. However, the Bonferroni method, which is
he usual procedure to control the overall error rate, is
otoriously stringent and risks erroneously accepting
he null hypothesis. Thus, we set the threshold for
tatistical signiﬁcance at .01 and reported 99% con-
dence intervals (CIs). As a conﬁrmatory analysis, we
sed the Benjamini-Hochberg procedure [36], a method
hat decreases the chance of incorrectly accepting the
ull hypothesis and is more forgiving than the Bonfer-
oni procedure. This analysis conﬁrmed our ﬁndings
Appendix).
ESULTS
atient Characteristics
There were 2626 patients in the CIBMTR who
et the inclusion criteria and had complete informa-
ion on donor/recipient sex/parity. In general, very
ew other data were missing (range of missing values,
able 3. Variables Examined in Multivariable Analysis: Main Effect o
Male N
ecipient
Male M-D ¡ M-R† 1007 (65) N
Nulliparous female M-D ¡ NF-R 145 (58) N
Parous female M-D ¡ PF-R 485 (60) N
Total 1637 (62)
M-D indicates male donor; M-R, male recipient; NF-R, nullipar
female donor; PF-D, parous female donor.
Reference group.%-5%). Two exceptions were donor transfusion his-ory in 884 cases (34%) and ABO compatibility in 643
24%) donor/recipient pairs.
Race categories are reported to the CIBMTR as
aucasian, Asian, Black, Native American, Hispanic,
r Other/Missing. There were small numbers of Asian
n  394), Black (n  73), Native American (n  6),
nd Hispanic (n  169) patients, and their effects on
ach endpoint were similar (data not shown). We
herefore decided to pool these groups into a single,
on-Caucasian group.
Recipient and donor pregnancy statuses were
trongly associated with one another (P  .001; Table
), and donor and patient age were also correlated
Spearman   .82, P  .001). Patient and donor age,
MV status, and donor transfusion history also dif-
able 4. Covariables Examined in Multivariate Analysis*
Variable Reference Comparator(s)
atient age — —
onor age — —
atient race Caucasian Others
isease type AML ALL
CML
isease risk Low Intermediate
High
nterval from
diagnosis to
transplant
<1 y >1 y
VHD prophylaxis CSA  MTX 
other
Others
BI in conditioning
regimen
No Yes
tem cell source Bone marrow Peripheral blood
BO compatibility† Compatible Minor incompatibility
Major incompatibility
onor history of
transfusion
No Yes
onor/recipient
CMV status
Negative/negative Negative/positive
Positive/negative
Positive/positive
GVHD, indicates graft-versus-host disease; TBI, total body irra-
diation; CMV, cytomegalovirus; AML, acute myelogenous leu-
kemia; CSA, cyclosporine; MTX, methotrexate; ALL, acute
lymphoblastic leukemia; CML, chronic myelogenous leukemia.
“Bidirectional” ABO incompatibility was classiﬁed as minor in-
/Recipient Pregnancy Status*
Donor, n (%)
ous Female Parous Female Total
M-R 153 (10) PF-D ¡ M-R 398 (25) 1558 (59)
NF-R 53 (20) PF-D ¡ NF-R 62 (24) 260 (10)
PF-R 71 (9) PF-D ¡ PF-R 252 (31) 808 (31)
7 (11) 712 (27) 2626
ale recipient; PF-R, parous female recipient; NF-D, nulliparousf Donor
ullipar
F-D ¡
F-D ¡
F-D ¡
27
ous femcompatibility (see text).
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Parity and GVHD 763ered across sex/parity groups (Table 2). Nulliparous
omen were younger than men and parous women,
hereas parous women were more likely to be CMV-
eropositive and to have undergone transfusion. Other
ovariables did not differ signiﬁcantly across sex/parity
roups. Sixty-two percent of all recipients received he-
atopoietic stem cell grafts from male donors.
The univariable hazard ratios (HRs) for the rela-
ion of each covariable to each endpoint were similar
o those reported in the literature (data not shown),
uggesting that our cohort of patients was similar to
ther patient populations.
urvival
Univariable models. Nulliparous female recipients
ad more favorable overall survival (unadjusted HR,
79; 95% CI, .64-.96; P  .02). Donor parity had no
ffect on overall survival.
Multivariable model. Disease type and risk, donor
nd patient age, use of total body irradiation, and type
f GVHD prophylaxis were independently associated
ith survival. After adjusting for these variables, there
as no effect of donor/recipient sex/parity on overall
urvival (P  .68, 8 df test).
able 5. Acute GVHD (n  2626)*
Recipient Male (n  1637)
ale (n  1558) 1.00 (reference), n  1007
ulliparous female (n  260) 1.15 (.85-1.54), P  .36, n  145
arous female (n  808) 1.01 (.84-1.22), P  .90, n  485
Multivariable hazard ratios (95% conﬁdence intervals) with ma
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Figure 1. Cumulative incidencedonor/recipient parity is 0.64 (8 df test).cute GVHD
Univariable models. There was an increased risk of
cute GVHD in patients who received grafts from
arous female donors (unadjusted HR, 1.16; 95% CI,
.00-1.34; P  .04). Cumulative incidence of acute
VHD at 100 days (Figure 1) was 38% for patients
eceiving grafts from parous women compared with
9% for those receiving grafts from nulliparous
omen (P .02) and 31% for recipients of male grafts
P .04). There was no difference between recipients of
ale versus nulliparous female donor grafts (P  .29).
Recipient parity had no effect on the risk of acute
VHD (data not shown).
Multivariable model. In addition to donor sex/parity,
isease type and risk, patient age, and use of total body
rradiation were associated with risk of acute GVHD.
fter adjusting for these factors in multivariable analysis,
onor/recipient sex/parity had no effect on risk of acute
VHD (P  .64, 8 df test; Table 5).
hronic GVHD
Univariable models. Donor sex/parity was an im-
ortant inﬂuence on risk of developing chronic
Donor
lliparous Female (n  277) Parous Female (n  712)
(.74-1.35), P  .99, n  153 1.17 (.97-1.42), P  .11, n  398
(.57-1.62), P  .88, n  53 1.18 (.77-1.80), P  .45, n  62
(.50-1.24), P  .31, n  71 1.14 (.91-1.43), P  .26, n  252
or/male recipient pairs as reference group. Overall P value for
3 4
t  Transplant_
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A. W. Loren et al.764VHD. Compared with male donors, parous female
onors imparted a signiﬁcantly greater risk of
hronic GVHD (unadjusted HR, 1.62; 95% CI,
.40-1.89; P  .01), as did nulliparous female do-
ors (unadjusted HR, 1.38; 95% CI, 1.12-1.71; P 
003). Cumulative incidences of chronic GVHD
ere 30% for patients receiving transplants from
ale donors, 39% for recipients of nulliparous fe-
ale donor grafts, and 41% for recipients of parous
emale donor grafts (Figure 2). The incidence of
hronic GVHD in patients receiving transplants
rom nulliparous female donors was not statistically
igniﬁcantly different from those receiving parous
emale donor grafts (P  .16).
There was no relation between recipient sex/
arity and chronic GVHD (data not shown).
Multivariable model. Sex/parity remained signiﬁ-
antly associated with chronic GVHD in multivari-
ble analysis. After accounting for donor and recip-
ent sex/parity, the only other covariable that
eached statistical signiﬁcance was patient age (HR,
.19 for each additional year of age; 95% CI, 1.01-
.39; P  .03).
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Figure 2. Cumulative incidence
able 6. Chronic GVHD (n  2112)*
Recipient Male (n  1304)
ale (n  1254) 1.00 (reference), n  805
ulliparous female
(n  213) .75 (.51-1.11), P  .15, n  117
arous female (n  645) .84 (.67-1.06), P  0.15, n  382
Multivariable hazard ratios (95% conﬁdence intervals) with male d
days. Overall P value for donor/recipient parity is .001 (8 df test).For male recipients, nulliparous and parous female
onors conferred an increased risk of chronic GVHD,
nd this increase was of similar magnitude (Table 6).
ompared with male donors, the HRs for chronic
VHD were 1.56 for parous female donors (P .001)
nd 1.44 for nulliparous female donors (P  .02).
For female recipients, pairwise analysis was re-
uired to directly compare the risk of chronic GVHD
mparted by each type of donor (see Methods). Parous
emale donors signiﬁcantly increased the risk of
hronic GVHD in nulliparous and parous female re-
ipients (Table 7). Table 7 presents the relative risk of
hronic GVHD in nulliparous female recipients. The
eference group is composed of male donor/nulliparous
emale recipient pairs. In nulliparous female recipi-
nts, risk of chronic GVHD from parous female do-
ors compared with male donors is 2.10 (99% CI,
.01-4.35; P  .009). Table 7 also presents the risk of
hronic GVHD in parous female recipients, with male
onor/parous female recipient pairs as the reference
roup. In parous female recipients, the HR for
hronic GVHD from parous female donors versus
ale donors is 1.49 (99% CI, 1.01-2.19; P  .008).
?Transplant
24 30 36
nic GVHD by donor sex/parity.
Donor
parous Female (n  234) Parous Female (n  574)
.07-1.95), P  .02, n  133 1.56 (1.26-1.94), P < .001, n  316
7-1.82), P  .95, n  42 1.58 (1.02-2.45), P  .04, n  54
5-2.08), P  .21, n  59 1.26 (.97-1.64), P  .08, n  204
ale recipient pairs as reference group for patients surviving 100nths Post
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Parity and GVHD 765econdary Endpoints
Univariable analyses were not performed for sec-
ndary endpoints.
Relapse. There was no relation between sex/parity
nd relapse risk (P  .39, 8 df; Table 8). As an explor-
tory analysis, we proceeded to estimate the HRs for
ach of the 9 donor/recipient combinations, with male
onor/male recipient pairs as the reference group.
he only group that demonstrated a decreased relapse
isk was male recipients of parous female donor grafts
HR, .75; 95% CI, .58-.97; P  .03). There was no
uch decreased risk in any other donor/recipient sex/
arity combination, including those who had an in-
reased risk of chronic GVHD.
Transplant-related mortality. Important covariables,
fter stratifying models by disease type and disease
tage due to nonproportional hazards, included pa-
ient and donor age, use of total body irradiation in
he conditioning regimen, 1 year from diagnosis to
ransplantation, type of GVHD prophylaxis, and
onor/recipient CMV status. After controlling for
hese variables, donor/recipient sex/parity had no ef-
ect on transplant-related mortality (P  .38, 8 df).
ISCUSSION
Parous female donors imparted an increased risk
f chronic, but not acute, GVHD in all recipients.
urther, all female donors (parous and nulliparous)
esulted in an increased risk of chronic GVHD in
ale recipients. The relation between sex/parity and
hronic GVHD remained strong despite adjusting for
ther important covariables. After accounting for sex/
arity, the only other variable that remained associ-
able 7. Chronic GVHD Pairwise Comparisons*
Male
ulliparous female recipients
(n  213) 1.00 (reference), n  117 1
arous female recipients
(n  645) 1.00 (reference), n  382 1
To account for multiple comparisons, only P values  .01 were
recipients are presented in the top row.
able 8. Relapse (n  2626)*
Recipient Male (n  1637)
ale (n  1558) 1.00 (reference), n  1007
ulliparous female
(n  260) 0.91 (.64-1.30), P  .60, n  145
arous female (n  808) .84 (.67-1.06), P  .14, n  485
Multivariable hazard ratios (95% conﬁdence intervals) with ma
donor/recipient parity is 0.39 (8 df test).ted with chronic GVHD was patient age. Somewhat
urprisingly, this increased risk of chronic GVHD did
ot translate into increased transplant-related mortal-
ty or decreased risk of relapse.
This study was the ﬁrst to evaluate the role of
ecipient pregnancy status in outcomes of SCT. For
he endpoints studied, there was no independent effect
f recipient sex/parity. However, the effects of recip-
ent sex/parity on other endpoints such as time to
ngraftment or graft failure are issues that will be
ddressed in future work.
Further, this is the only multicenter study in the
odern transplantation era to evaluate the effect of
ex mismatching. We conﬁrmed that female-to-male
ransplants result in a higher rate of chronic GVHD.
he ﬁnding that nulliparous female donors confer a
isk of chronic GVHD similar to that of parous female
onors may reﬂect the development after transplanta-
ion of cytotoxic T cells reactive against H-Y antigens,
everal of which have been identiﬁed as T-cell targets
37-39]. Anti–H-Y alloimmunization could also be
ediated by antibodies. Antibodies to Y-encoded pep-
ides have been detected in male recipients of female
tem cells after transplantation [25,26], and normal
omen (pregnancy status unknown) harbor antibodies
o H-Y antigens [26]. An alternative explanation is
hat women who reported nulliparity may in fact have
een pregnant in the past, a pregnancy of which they
ay or may not have been aware.
It is notable that 62% of all donors were male,
hich is more than one would expect by chance and
ay reﬂect many clinicians’ preference to choose
onors who are male or sex matched (59% of recipi-
nts were male). Importantly, however, the increased
Donor
ulliparous Female Parous Female
8-3.27), P  .38, n  42 2.10 (1.01-4.35), P  .009, n  54
4-2.91), P  .059, n  59 1.49 (1.01-2.19), P  .008, n  204
ered signiﬁcant, and 99% conﬁdence intervals are shown. Male
Donor
lliparous Female (n  277) Parous Female (n  712)
(.73-1.42), P  .90, n  153 .75 (.58-0.97), P  .03, n  398
(.64-1.76), P  .83, n  53 1.03 (.63-1.68), P  .91, n  62
(0.38-1.16), P  .15, n  71 1.00 (.76-1.30), P  .99, n  252
or/male recipient pairs as reference group. Overall P value forN
.35 (.5
.57 (.8
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A. W. Loren et al.766isk of chronic GVHD in female recipients supports
he hypothesis that autosomal minor histocompatibil-
ty antigens also play an important role in GVHD
athophysiology.
We attempted to account for other mechanisms of
lloimmunization, such as previous blood transfu-
ions, by creating an “alloimmunized” group of do-
ors that included parous women plus all male and
ulliparous female donors who reported previous
lood transfusion. A sensitivity analysis duplicating
ll of the statistical models for the 3 primary end-
oints (survival and acute and chronic GVHD)
ompared alloimmunized with non-alloimmunized
onors. Although limited by the very small number
f these additional alloimmunized donors (n  24),
ncluding them did not signiﬁcantly alter the re-
ults.
Despite its large sample of 2626, this study may
ave been underpowered to answer some important
uestions. There were 4 areas in particular that may
ave been at a disadvantage from inadequate sample
ize. (1) The nulliparous female groups, recipient and
onor, were quite small, making it difﬁcult to draw
ecisive conclusions from comparisons involving these
roups. (2) Pairwise analysis also had lack of power,
hich was exacerbated by the more conservative
value chosen to indicate statistical signiﬁcance. (3)
here were insufﬁcient data to explore the hypothesis
hat there may be a “dose-response” relation with
regnancy (ie, that a larger number of donor pregnan-
ies confers an increasingly higher risk of GVHD in
ecipients). (4) Although the overall P value for the
ffect of sex/parity on relapse risk was not statistically
igniﬁcant, an exploratory evaluation of the HRs and
5% CIs for each donor/recipient pair suggested that
ale recipients of parous female donor grafts may
ave a lower risk of relapse. If conﬁrmed, this could
ave important implications on targeting immuno-
herapy to H-Y antigens.
This is the largest study to examine the effect of
onor parity, and the only study to create a compre-
ensive model evaluating the effects of recipient/
onor sex/parity on outcomes of HLA-identical sib-
ing allogeneic SCT. We have established that donor
arity is an important risk factor for the development
f chronic GVHD, not just in male recipients but also
n female recipients. The pathophysiology, tradition-
lly attributed to pregnancy-induced alloimmuniza-
ion against minor histocompatibility antigens, in par-
icular those encoded by the Y-chromosome, requires
lucidation. A major question that cannot be ad-
ressed by this study is the biologic mechanism un-
erlying these observations. Parity is at best a “surro-
ate exposure.” The true immunologic implications of
revious pregnancies are unclear. Although alloimmu-
ization clearly occurs in some women, others become
olerant to fetal antigens. Up to 75% of parous women Say harbor cells of fetal origin for decades after preg-
ancy, thus creating a long-term state of microchi-
erism [40-42]. Although this observation was ﬁrst
ade in the 1970s, recent work has highlighted the
requency with which this phenomenon is observed
43]. The activity and importance of these chimeric
ells have never been evaluated directly in the setting
f SCT, but several groups have begun to exploit
aternal tolerance to fetal antigens by demonstrating
hat non–T-cell–depleted haploidentical transplants
etween children and their microchimeric mothers
both child to mother and mother to child) have lower-
han-expected rates of graft rejection and GVHD
44-46]. Conversely, fetal exposure to maternal anti-
ens also occurs, as evidenced by the detection of
aternal cells in umbilical cord blood [47-50] and in
reast milk [51]. A retrospective registry-based study
52] and a prospective small trial [53] demonstrated
hat haploidentical sibling transplants from donors
ho are mismatched at the maternal allele (ie, the
llele shared by the sibling pair is paternally derived)
lso carry a relatively lower risk of GVHD than other
aploidentical transplants. This observation supports
he hypothesis that offspring are tolerant to noninher-
ted maternal antigens.
Cells of fetal origin are pluripotent and can dif-
erentiate into several different cell types, including
cells [54], granulocytes [12], hepatocytes [55], and
hyroid tissue [56]. They have thus been dubbed
pregnancy-associated progenitor cells” [57]. It is
lear that fetal microchimerism is not immunologi-
ally silent. These cells may have an important role in
he initiation and propagation of disease [42,58,59]
nd seem to target and proliferate in areas of tissue
amage and inﬂammation [60]. Further, they are de-
ectable in peripheral blood stem cell products [61].
hese cells might serve as mediators of GVHD if they
re transplanted from a parous woman into a patient.
hus, the different possible effects of pregnancy—
lloimmunization, microchimerism as a reﬂection (or
source) of tolerance, or microchimerism as a reser-
oir of haploidentical stem cells infused with the do-
or’s HLA-identical stem cells—would theoretically
ave very different effects on the outcomes of trans-
lantation. Simply labeling a donor as parous may
ask a very heterogeneous population of women.
Future studies to evaluate the effects of preg-
ancy on the maternal immune system will offer
dditional insight into the physiology underlying
he observations from this retrospective registry-
ased study. Until these mechanisms are better un-
erstood, it is appropriate to avoid parous female do-
ors and preferentially to choose male donors for male
ecipients whenever possible for HLA-identical sibling
CT.
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PPENDIX. A
B-H Procedure to Test for Statistical Signiﬁcance
f Hazard Ratios for Chronic GVHD in Pairwise
nalysis*
Comparison P B-H Threshold
D ¡ MR† vs PFD ¡ MR† <.0001 .0056
D ¡ PFR† vs PFD ¡ PFR† .0083 .0111
D ¡ NFR† vs PFD ¡ NFR† .0088 .0167
D ¡ MR† vs NFD ¡ MR† .0161 .0222
D ¡ PFR vs NFD ¡ PFR .0591 .0278
FD ¡ NFR vs PFD ¡ NFR .2207 .0333
D ¡ NFR vs NFD ¡ NFR .3809 .0389
FD ¡ MR vs PFD ¡ MR .6327 .0444
FD ¡ PFR vs PFD ¡ PFR .828 .0500
B-H indicates Benjamini-Hochberg; MD, male donor; MR, male
recipient; PFR, parous female recipient; NFR, nulliparous fe-
male recipient; PFD, parous female donor; NFD, nulliparous
female donor. Comparisons are listed according to magnitude of
P value (in ascending order).
According to the B-H procedure, if the P value is lower than the
B-H threshold, the comparison is statistically signiﬁcant [35].
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